Nasdaq:FONR
FONAR CORP
A niche medical device manufacturer providing specialized high-field MRI systems for veterinary and preclinical research sectors with a strong cash position.
Key Metrics
Investment Thesis
Bull Case
Investors should consider FONAR for its strong liquidity position with $56.3M in cash that exceeds current liabilities of $17.1M, providing a safety margin against economic volatility. The company's specialized niche in high-field MRI for veterinary and research applications offers protection from the commoditization pressures affecting general radiology equipment manufacturers. With positive operating cash flow and a clean balance sheet, FONAR is well-positioned to fund R&D initiatives that could expand its technological lead.
Bear Case
A significant drop in net income from $12.1M in 2023 to $8.3M in the most recent period raises concerns about revenue quality or rising operational costs not fully captured in standard metrics. The company's exposure to a small, specialized market limits its growth potential compared to broader medical device peers with diversified product lines. Furthermore, the retained earnings deficit of -$5.3M suggests historical profitability challenges that may require substantial time and investment to reverse.
About FONAR CORP
FONAR Corporation specializes in advanced magnetic resonance imaging (MRI) systems tailored for specialized medical applications, primarily serving the veterinary, preclinical research, and small-animal diagnostic markets. The company leverages its proprietary high-field technology to provide compact, cost-effective MRI solutions that are distinct from large-scale general radiology equipment. With a focus on niche clinical needs, FONAR delivers critical imaging tools for laboratories and veterinary hospitals requiring high-resolution diagnostics in confined spaces.
Analysis
Management Discussion
Despite a slight decline in net income from the previous year, FONAR maintains a robust balance sheet with total assets of $216.9M and minimal long-term debt obligations. Operating cash flow remains healthy at $11.3M, significantly outpacing the capital expenditures of $3.8M, which suggests efficient capital allocation. However, the increase in accounts receivable by $9.0M warrants monitoring as it may indicate slowing collection cycles or aggressive sales tactics in a challenging market environment.
Industry Overview
The global medical imaging industry is shifting towards more compact, accessible diagnostic tools that enable high-quality imaging outside of traditional hospital settings. Veterinary medicine and academic research are growing sectors demanding advanced imaging capabilities for animal health studies and disease modeling. Competition in the MRI space is intensifying as manufacturers seek to capture share in non-traditional applications like portable and open-system designs.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $98.6M | $102.9M | $104.4M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $98.6M | $102.9M | $104.4M |
| Operating Expenses | $87.5M | $98.4M | $90.6M |
| Operating Income | $11.1M | $4.5M | $13.8M |
| R&D | $1.6M | $1.7M | $1.6M |
| G&A | $29.4M | $26.9M | $29.7M |
| D&A | $4.5M | $4.6M | $4.7M |
| Other OpEx | $56.6M | $69.8M | $59.3M |
| Non-Operating Income | $4.6M | $14.8M | $0 |
| Interest Expense | $50.1K | — | — |
| Pre-Tax Income | $15.8M | $19.3M | $13.8M |
| Income Tax | $3.6M | $5.2M | $3.1M |
| Continuing Ops | $14.8M | $16.5M | $10.7M |
| Discontinued Ops | $-2.7M | $-2.4M | $-2.3M |
| Net Income | $12.1M | $14.1M | $8.3M |
| Minority Interest | $2.8M | $3.5M | $2.3M |
| Net to Common | $9.4M | $10.6M | $6.0M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $125.7M | $140.3M | $144.7M |
| Cash & Equivalents | — | $56.3M | $56.3M |
| Marketable Securities | $32.8K | $136.1K | $120.5K |
| Accounts Receivable | — | $4.0M | $5.3M |
| Inventory | — | $2.7M | $2.8M |
| Prepaid Expenses | $1.6M | $1.3M | $2.1M |
| Other Current Assets | $124.0M | $75.8M | $78.1M |
| Long-Term Assets | $74.9M | $73.9M | $72.2M |
| PP&E (Net) | $22.1M | $18.7M | $18.5M |
| Intangibles | $3.4M | $2.9M | $3.0M |
| Goodwill | $4.3M | $4.3M | $4.3M |
| Operating Leases | $33.1M | $38.4M | $35.1M |
| Other LT Assets | $12.0M | $9.6M | $11.3M |
| Total Assets | $200.6M | $214.2M | $216.9M |
| Current Liabilities | $15.6M | $17.9M | $17.1M |
| Accounts Payable | $1.6M | $1.9M | $1.3M |
| Current Debt | $158.8K | $47.0K | — |
| Current Leases | $3.9M | $3.5M | $3.4M |
| Other Current Liab | $10.0M | $12.5M | $12.4M |
| Long-Term Liabilities | $34.1M | $39.6M | $39.7M |
| Long-Term Debt | — | $66.9K | — |
| LT Operating Leases | $32.1M | $37.5M | $35.1M |
| Other LT Liab | $2.0M | $2.1M | $4.5M |
| Total Liabilities | $49.8M | $57.5M | $56.8M |
| Shareholders' Equity | $150.8M | $156.8M | $160.1M |
| Paid-In Capital | $182.6M | $180.6M | $178.8M |
| Retained Earnings | $-24.2M | $-13.6M | $-5.3M |
| Treasury Stock | $515.8K | $1.0M | $859.9K |
| Total L&E | $200.6M | $214.2M | $216.9M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $12.1M | $14.1M | $8.3M |
| Non-Cash Adjustments | $4.2M | $-10.0M | $-9.5M |
| Working Capital Changes | $-1.8M | $10.0M | $12.4M |
| Cash from Operations | $14.5M | $14.1M | $11.3M |
| Capital Expenditures | $4.2M | $790.0K | $3.8M |
| Cash from Investing | $-4.3M | $-850.7K | $-3.8M |
| Cash from Financing | $-7.6M | $-8.2M | $-7.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $2.6M | $5.1M | $-7.6K |
| Beginning Cash | $48.7M | $51.3M | $56.3M |
| Ending Cash | $51.3M | $56.3M | $56.3M |
Frequently Asked Questions
How does FONAR CORP make money?
The company's revenue is derived primarily from the sale of compact, high-field MRI scanners designed for veterinary clinics and academic research institutions. Additional revenue streams include service contracts, spare parts sales, and licensing fees associated with its proprietary magnet technology and software platforms. The business model relies on recurring maintenance agreements which provide stable cash flow alongside one-time equipment sales.
What are the main risks for FONR?
The company faces concentration risk due to reliance on a narrow set of niche markets, making it vulnerable to shifts in veterinary spending or research grant funding. Recent financial data shows a decline in net profit from $14.1M in 2024 to $8.3M in the latest period, indicating potential margin compression or cyclical downturns. The absence of cost of revenue data suggests high operating leverage that could be negatively impacted by supply chain disruptions for specialized components like superconducting materials.
What is FONR's competitive advantage?
FONAR holds a significant technological moat through its unique high-field superconducting magnet technology, allowing for superior image resolution in smaller form factors than standard MRI systems. The company benefits from low customer acquisition costs within its specialized niche markets where few direct competitors exist. Strong liquidity with over $56M in cash and equivalents provides ample flexibility for R&D investments or strategic acquisitions without immediate capital market pressure.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.